Actively Recruiting
Hyperemic mYocardial Perfusion by adEnosine at diffeRent Doses
Led by Region Skane · Updated on 2025-06-27
180
Participants Needed
1
Research Sites
114 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Adenosine is a commonly used pharmaceutical stressor at cardiac magnetic resonance examinations to assess suspected chronic coronary syndrome (CCS). However, several studies have reported that the current use of adenosine does not induce adequate hyperemic response in a substantial number of patients, leading to false diagnostics. The aim of this trial is to investigate the hyperemic effect of the standard dose of adenosine (140 microgram/kg/min) to the high dose of adenosine (210 microgram/kg/min) to improve the diagnostic methods using adenosine as a stressor and ultimately improve treatment decisions and patient prognosis in CCS.
CONDITIONS
Official Title
Hyperemic mYocardial Perfusion by adEnosine at diffeRent Doses
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participants must provide written consent to participate in the trial
- Referred to the Department of Clinical Physiology, Skåne University Hospital, for suspected or known chronic coronary syndrome or heart failure
- Includes males and females with 6 participants of each sex in every age decade from 40 to over 80 years old
- Participants either have no known heart failure or have known heart failure
- No caffeine intake within 24 hours prior to the examination
- Healthy volunteers must also provide written consent
- Healthy volunteers must meet the same age and sex group criteria as patients
- Healthy volunteers must have no caffeine intake within 24 hours prior to the examination
You will not qualify if you...
- Acute referral or being an in-house patient
- Clinically unstable condition
- Experiencing acute chest pain
- Severe or decompensated heart failure
- Non-sinus heart rhythm, such as atrial fibrillation
- Asthma or severe chronic obstructive pulmonary disease
- Known chronic renal failure with eGFR less than 45 mL/min/1.73m2
- AV-block II or III
- Left bundle branch block
- Resting systolic blood pressure less than 90 mmHg or greater than 230 mmHg
- Increased intracranial pressure
- Known allergy or adverse reaction to adenosine or mannitol
- Known allergy or adverse reaction to gadolinium contrast agents
- Treatment with medications containing dipyridamole or theophylline
- Claustrophobia
- Devices contraindicated to cardiac MRI imaging, such as pacemakers or intracranial clips
- Pregnancy or breastfeeding
- Inability to give informed consent due to mental state or language difficulties
- For healthy volunteers: any patient exclusion criteria
- Blood pressure greater than 140/90 measured by clinical routine
- Known systemic disease
- Known cardiac disease
- Use of cardiovascular medication
- Use of medication that might influence cardiovascular health
- Smoking
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Clinical Physiology, Department of Clinical Sciences Lund, Lund University, Skåne University Hospital
Lund, Sweden
Actively Recruiting
Research Team
H
Henrik Engblom, MD, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
CROSSOVER
Primary Purpose
DIAGNOSTIC
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here